2 474

Cited 16 times in

Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial

 Jaeheon Jeong  ;  Byoung Chul Cho  ;  Joo Hyuk Sohn  ;  Hye Jin Choi  ;  Se Hyun Kim  ;  Young Joo Lee  ;  Min Kyu Jung  ;  Sang Joon Shin  ;  Moo-Suk Park  ;  Se Kyu Kim  ;  Joon Chang  ;  Joo Hang Kim 
 LUNG CANCER, Vol.70(1) : 77-81, 2010 
Journal Title
Issue Date
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Camptothecin/administration & dosage ; Camptothecin/adverse effects ; Camptothecin/analogs & derivatives* ; Camptothecin/therapeutic use ; Carcinoma, Small Cell/drug therapy* ; Disease-Free Survival ; Female ; Humans ; Lung Neoplasms/drug therapy* ; Male ; Middle Aged ; Organoplatinum Compounds/administration & dosage ; Salvage Therapy ; Topoisomerase I Inhibitors/adverse effects ; Topoisomerase I Inhibitors/therapeutic use*
Belotecan ; SCLC ; Topoisomerase I inhibitor
BACKGROUND: Belotecan is a topoisomerase I inhibitor. This phase II trial was conducted to evaluate the efficacy and toxicity of belotecan in relapsing small-cell lung cancer (SCLC) patients after irinotecan failure.

PATIENTS AND METHODS: SCLC patients, who had relapsed at least 3 months after achieving objective response to irinotecan plus platinum chemotherapy, were eligible. Belotecan was administered at a dose of 0.5 mg/m(2)/day for 5 consecutive days every 3 weeks.

RESULTS: Twenty-seven patients were enrolled in this study. Twenty-five patients were evaluated for response, and 27 patients were evaluated for toxicity and survival. The overall response rate was 22%. The median time to progression was 4.7 months (95% CI, 3.6-5.8 months), and the median overall survival was 13.1 months (95% CI, 10.4-15.8 months). The most frequent grade 3/4 toxicities were neutropenia (93%) and thrombocytopenia (48%). There was one treatment-related death due to pneumonia.

CONCLUSION: Belotecan showed modest activity and manageable toxicities in relapsing SCLC patients in this study which was conducted in Asia. But further study in Caucasian patients is needed.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Se Kyu(김세규)
Kim, Se Hyun(김세현)
Kim, Joo Hang(김주항)
Park, Moo Suk(박무석) ORCID logo https://orcid.org/0000-0003-0820-7615
Sohn, Joo Hyuk(손주혁) ORCID logo https://orcid.org/0000-0002-2303-2764
Shin, Sang Joon(신상준) ORCID logo https://orcid.org/0000-0001-5350-7241
Chang, Joon(장준) ORCID logo https://orcid.org/0000-0003-4542-6841
Jung, Min Kyu(정민규) ORCID logo https://orcid.org/0000-0001-8281-3387
Jung, Jae Hun(정재헌)
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
Choi, Hye Jin(최혜진) ORCID logo https://orcid.org/0000-0001-5917-1400
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.